Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/2/2019
SIETES contiene 92664 citas

 1 a 20 de 584 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102851]
2.Enlace a cita original Cita con resumen
Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB, Thielen LA, Li P, Shalev A. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 2018:9 de julio. [Ref.ID 102718]
3. Cita con resumen
Anónimo. Semma Therapeutics raises $114 million for new diabetes treatment. DIA Daily 2017:1. [Ref.ID 102151]
4.Enlace a cita original Cita con resumen
Anónimo. Actualización de insulinas. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-10. [Ref.ID 101631]
5. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
7.Enlace a cita original Cita con resumen
Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium–glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2015;38:2258-65. [Ref.ID 99841]
8. Cita con resumen
Anónimo. Insulin degludec (Tresiba) - A new long-acting insulin for diabetes. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:163-4. [Ref.ID 99817]
9. Cita con resumen
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, SAenz AM, Beck RW, Nadeau KJ, for the T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 2015;314:2241-50. [Ref.ID 99792]
10. Cita con resumen
Mesa J. Nuevas insulinas en la diabetes tipo 1. Med Clin (Barc) 2015;145:70-5. [Ref.ID 99322]
12.Enlace a cita original Cita con resumen
Lipska KJ, Ross JS, MIao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175:356-62. [Ref.ID 98764]
13. Cita con resumen
14. Cita con resumen
Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, Harrington A, Wilson C, Tsouros S, Soobiah C, Yu CH, Hutton B, Hoch JS, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 2014;349:g5459. [Ref.ID 98278]
15. Cita con resumen
Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW, for the OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014;384:1265-72. [Ref.ID 98153]
16. Cita con resumen
Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. Generation of functional human pancreatic ß cells in vitro. Cell 2014;159:428-39. [Ref.ID 98149]
17. Cita con resumen
Anónimo. Inhaled insulin is licensed in the US. BMJ 2014;349:g4498. [Ref.ID 98126]
18.Enlace a cita original Cita con resumen
Anónimo. FDA approves Afrezza to treat diabetes. FDA U.S. Food and Drug Administration 2014:27 de junio. [Ref.ID 97765]
19. Cita con resumen
Larkin ME, Barnie A, Braffett BH, Cleary PA, Diminick L, Harth J, Gatcomb P, Golden E, Lipps J, Lorenzi G, Mahony C, Nathan DM, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Musculoskeletal complications in type 1 diabetes. Diabetes Care 2014;37:1863-9. [Ref.ID 97742]
20. Cita con resumen
Anónimo. FDA panel recommends approval for inhaled form of insulin. DIA Daily 2014:1. [Ref.ID 97391]
Seleccionar todas
 1 a 20 de 584 siguiente >>